

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/H044E79B929EN.html>

Date: September 2018

Pages: 150

Price: US\$ 3,500.00 (Single User License)

ID: H044E79B929EN

Abstracts

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Histone Deacetylase 1 - Pipeline Review, H2 2018'; Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

The report 'Histone Deacetylase 1 - Pipeline Review, H2 2018' outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued

projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 6, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Non-Small Cell Lung Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Diffuse Large B-Cell Lymphoma, Lung Cancer, Melanoma, Mycosis Fungoides, Myelodysplastic Syndrome, Neuroblastoma, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Colon Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Essential Thrombocythemia, Liver Cancer, Lymphoma, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Sickle Cell Disease, Thalassemia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liver Fibrosis, Lung Adenocarcinoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sezary Syndrome, Skin Cancer, Soft Tissue Sarcoma, Solid Tumor, Systemic Lupus Erythematosus, Thyroid Cancer and

Unspecified.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.4), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Products under Development by Companies, H2 2018 (Contd.7), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 4D Pharma PLC, H2 2018
Pipeline by 4SC AG, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by Curis Inc, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by Italfarmaco SpA, H2 2018
Pipeline by Medivir AB, H2 2018
Pipeline by MEI Pharma Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Mirati Therapeutics Inc, H2 2018
Pipeline by Syndax Pharmaceuticals Inc, H2 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd.1), H2 2018

Dormant Products, H2 2018 (Contd.2), H2 2018

Dormant Products, H2 2018 (Contd.3), H2 2018

Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

4D Pharma PLC

4SC AG

AlfaSigma SpA

Celgene Corp

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

Italfarmaco SpA

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Mirati Therapeutics Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

I would like to order

Product name: Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/H044E79B929EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H044E79B929EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970